At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Capecitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
In Brief
A Phase 2 clinical trial evaluating Capecitabine, Temozolomide, and 1 other intervention for Gastrinoma and 8 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartDec 2012
Primary CompletionJan 2018
Study CompletionDec 2019
TodayJul 2026
First PostedFeb 2, 2012
Enrollment StartDec 1, 2012
Primary CompletionJan 1, 2018
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 14.4 years ago
Interventions
Capecitabinedrug
Capecitabine by mouth twice daily on Days 1 to 14
Temozolomidedrug
Temozolomide by mouth daily on Days 10 to 14
Bevacizumabbiological
Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15